RO5479599 + erlotinib

RO5479599 + erlotinib is an investigational **combination therapy** evaluated primarily in oncology clinical trials, specifically for the treatment of metastatic and/or locally advanced malignant human epidermal growth factor receptor (EGFR)-dependent tumors including non-small cell lung cancer (NSCLC). - **RO5479599** is an experimental small molecule (precise target and mechanism not publicly detailed). - **Erlotinib** is a well-characterized, FDA-approved small molecule and a reversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, used in various cancers (especially NSCLC with EGFR mutations). The combination is being studied to enhance anti-tumor activity through dual targeting, particularly to overcome resistance observed with monotherapies targeting EGFR.